Osivax completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033 48 healthy volunteers enrolled in first-in-human trial Topline data read-out expected by Q4 2024 Lyon, France – June 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has completed …
Archives de l’étiquette : OVX033
ISIDORe User’s conference
Online – Oral PresentationCharlotte Primard, Non-Clinical Project Manager of Osivax, to provide an update on OVX033 as part of a presentation entitled “Immunogenicity, cross-reactivity and poly-functionality of immune responses induced by OVX033 with and without SQ for SARS-CoV-2”.
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 Phase 1 study to evaluate safety and immunogenicity of sarbecovirus (coronavirus) vaccine candidate, OVX033, at ascending dose levels The trial will enroll 48 participants in France Lyon, France – February 15, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against …
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033 in Frontiers in Immunology
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033in Frontiers in Immunology Evidence of cross-protection against multiple SARS-CoV-2 variants of concern observed in hamster challenge model Lyon, France – July 06, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the publication of promising preclinical …